BiotechTube

Saizen® A + Saizen® B

Phase 3Completed
2 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Children Born With Serious Intra-uterine Growth Retardation

Conditions

Children Born With Serious Intra-uterine Growth Retardation

Trial Timeline

Nov 1, 1998 → Feb 1, 2010

NCT ID
NCT01400698

About Saizen® A + Saizen® B

Saizen® A + Saizen® B is a phase 3 stage product being developed by Merck for Children Born With Serious Intra-uterine Growth Retardation. The current trial status is completed. This product is registered under clinical trial identifier NCT01400698. Target conditions include Children Born With Serious Intra-uterine Growth Retardation.

What happened to similar drugs?

0 of 12 similar drugs in Children Born With Serious Intra-uterine Growth Retardation were approved

Approved (0) Terminated (1) Active (11)
🔄Exenatide Once Weekly + PlaceboAstraZenecaPhase 3
🔄MEDI3250 + PlaceboAstraZenecaPhase 3
🔄MEDI3250AstraZenecaPhase 3
❌Budesonide Formoterol Drug Combination + nebulisation of terbutalineAstraZenecaPhase 3
🔄RotaTeq (V260) + IPVMerckPhase 3
🔄HydroxyureaNovartisPhase 3
🔄Somapacitan + Norditropin®Novo NordiskPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01400698Phase 3Completed

Competing Products

20 competing products in Children Born With Serious Intra-uterine Growth Retardation

See all competitors
ProductCompanyStageHype Score
Quizartinib + Etoposide + Dexrazoxane + Mitoxantrone + Cytarabine + Methotrexate + Daunorubicin + FludarabineDaiichi SankyoPhase 2
42
RSS0393 OintmentJiangsu Hengrui MedicinePhase 2
42
Ceftazidime-avibactamAbbViePhase 1
21
Exenatide Once Weekly + PlaceboAstraZenecaPhase 3
40
MEDI3250 + PlaceboAstraZenecaPhase 3
40
MEDI3250AstraZenecaPhase 3
40
Budesonide Formoterol Drug Combination + nebulisation of terbutalineAstraZenecaPhase 3
32
zolinza/vorinostatMerckPhase 1/2
32
RotaTeq (V260) + IPVMerckPhase 3
40
HydroxyureaNovartisPhase 3
47
Norditropin® FlexPro®Novo NordiskPre-clinical
33
Somapacitan + Norditropin®Novo NordiskPhase 3
40
Somapacitan + Norditropin®Novo NordiskPhase 2
39
somapacitan + Norditropin®Novo NordiskPhase 3
40
SomapacitanNovo NordiskPre-clinical
33
VoxelotorPfizerPhase 2
27
Sildenafil citrate + Sildenafil citrate + Placebo + Sildenafil citratePfizerPhase 3
40
Copanlisib (BAY806946)BayerPhase 1/2
21
EptinezumabLundbeckPhase 1
26
Eptinezumab + PlaceboLundbeckPhase 3
44